Cytonus Therapeutics
Dr. Moomiaie-Qajar has served as Cytonus’ Chief Executive Officer since our inception, having successfully led the spin-out of Cytonus from University of California San Diego (UCSD) in 2018 to change the paradigm of disease using Cytonus’ platform of Bio-Drone therapeutics called Cargocytes. He is a trained surgeon from Yale University with a long history of developing innovative technologies in medicine and transforming them into commercially-viable products. Remo holds multiple US and international patents, and has 15 years of experience incubating technologies from venture-stage to exit. Dr. Moomiaie-Qajar’s background as an academic researcher, physician, and entrepreneur brings a unique trifecta of perspective and experience to Cytonus.
This person is not in any offices
Cytonus Therapeutics
Cytonus Therapeutics has developed a first-in-class “biologic drone” called the Cargocyte. The Cargocyte is a platform to deliver therapeutics in a precise, controlled, safe and reproducible manner. Cytonus’ innovative approach delivers on the long sought after promises of drug delivery, to deliver the right drug at the right dose to the right tissue.